Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.
Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.
Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.
Kura Oncology (Nasdaq: KURA) reported the U.S. FDA approval and commercial launch of KOMZIFTI (ziftomenib) for adults with relapsed/refractory NPM1-mutated AML and disclosed preliminary commercial and collaboration financials. KOMZIFTI generated $2.1 million net product revenue from first sale (Nov 21–Dec 31, 2025). The company received $195 million in milestone payments, holds $667.3 million in cash and short-term investments as of Dec 31, 2025, and expects $45–$55 million non-cash collaboration revenue in 2026.
Key 2026 priorities include accelerating KOMZIFTI uptake, presenting KOMET-007/KOMET-017 data, expanding combinations, and advancing darlifarnib and next-generation programs.
Kura Oncology (Nasdaq: KURA) announced that on January 2, 2026 its Compensation Committee granted inducement nonstatutory stock options to three new employees under the company’s 2023 Inducement Option Plan.
The grants total 49,750 options with an exercise price of $10.34 per share (the closing price on January 2, 2026). The options vest over four years: 25% of the shares vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service. Grants are subject to the plan and applicable option agreements and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported KOMZIFTI (ziftomenib) combined with venetoclax and azacitidine showed strong activity and a manageable safety profile in NPM1-mutated and KMT2A-rearranged AML at ASH 2025.
Key data: newly diagnosed NPM1-m CRc 86% (37 evaluable) and CR 73% with 68% of CRc responders achieving molecular MRD negativity; median CR and OS not reached at 26.1-week median follow-up. In R/R NPM1-m ORR 65% (83 pts; CRc 48%; CRc median duration 39.9 weeks) and higher responses in venetoclax-naïve patients. In R/R KMT2A-r ORR 41% (CRc 28%; median OS 21.1 weeks). Combination was generally well tolerated.
Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.
Kura Oncology (Nasdaq: KURA) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib). Under Kura's collaboration and license agreement with Kyowa Kirin, the sale triggers a $135 million milestone payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. This payment represents a near-term cash inflow tied to commercialization activity for the newly approved therapy.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin announced that KOMZIFTI (ziftomenib) has been added to the National Comprehensive Cancer Network Guidelines as a Category 2A recommended option for adults with relapsed/refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation.
KOMZIFTI received full FDA approval on November 13, 2025 and is commercially available in the U.S. The approval was supported by KOMET-001 data showing a 21.4% CR/CRh rate and a median duration of CR/CRh of 5 months. The drug is available through a limited network of specialty pharmacies and distributors.
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin announced FDA approval of KOMZIFTI (ziftomenib) on November 13, 2025 for adult patients with relapsed or refractory NPM1‑mutated acute myeloid leukemia (R/R NPM1‑m AML) with no satisfactory alternative options.
Approval is based on the KOMET‑001 trial (N=112): CR+CRh 21.4% (95% CI: 14.2, 30.2), median duration of CR+CRh 5.0 months, median time to first response 2.7 months. KOMZIFTI is the first once‑daily oral menin inhibitor approved; label includes a boxed warning for differentiation syndrome but no boxed warning for QTc prolongation.
Kura Oncology (Nasdaq: KURA) will participate in the Jefferies Global Healthcare Conference on November 19, 2025. The company is scheduled to present at 3:30 p.m. GMT / 10:30 a.m. ET / 7:30 a.m. PT.
A live audio webcast will be available in the Investors section of Kura Oncology's website, with an archived replay posted after the event.
Kura Oncology (Nasdaq: KURA) announced that on November 3, 2025 its Compensation Committee granted inducement nonstatutory stock options to a new non-executive employee under the company's 2023 Inducement Option Plan, as amended.
The grant totals 21,750 options with an exercise price of $9.77 per share (the closing price on November 3, 2025). Options vest over four years: 25% at one year then monthly over the following 36 months, subject to continued service, and are governed by the plan and a stock option agreement. The committee approved the award as an inducement in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) reported third quarter 2025 results and a corporate update on Nov 4, 2025. Key clinical milestones include an FDA Priority Review for ziftomenib in R/R NPM1‑mutant AML with a PDUFA date of Nov 30, 2025, initiation and first‑patient dosing in the pivotal KOMET‑017 Phase 3 trials in frontline AML, and dosing in KOMET‑007 FLT3 cohort. Two oral ASH 2025 presentations will feature ziftomenib combination data. ESMO 2025 data highlighted activity for FTIs darlifarnib and tipifarnib in solid tumors. Financially, Kura reported $609.7M pro forma cash (including two $30M Kyowa Kirin milestones) and said cash should fund operations into 2027 and support KOMET‑017 topline results.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
